head and neck squamous cell carcinoma
Conditions
Sponsors
Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The pathological type is type II-III (WHO classification: type I: keratinizing squamous cell carcinoma; type II: non-keratinizing squamous cell carcinoma; type III: undifferentiated carcinoma). 2. Aged 20 to 75 years. 3. The clinical stage is III-IV A (AJCC 8th edition). 4. No distant transfer. 5. Cassette score >= 80 points, and no serious underlying diseases. 6. Use intensity-modulated radiation therapy (IMRT).
Exclusion criteria
Exclusion criteria: 1. Severe underlying diseases of the heart or lungs. 2. The estimated survival time is less than 1 year. 3. Contraindications to radiotherapy. 4. Before the study and treatment, had active or previous autoimmune diseases or inflammatory diseases (including inflammatory bowel disease [such as colitis or Crohn's disease], diverticulitis (except diverticulosis), diarrhea in the last 3 years related abdominal disease or other serious chronic gastrointestinal diseases), systemic lupus erythematosus, sarcoidosis or Wegener syndrome (granulomatosis with vasculitis), Graves' disease, rheumatoid arthritis, hypophysitis, uveitis Yan etc. For this standard, the following exceptions are: patients with vitiligo or hair loss;-patients with hypothyroidism (such as after Hashimoto's syndrome) and stable disease on hormone replacement therapy, or patients with psoriasis who do not require systemic treatment. 5. A history of active primary immunodeficiency. 6. Active infection, including tuberculosis (clinical evaluation), hepatitis B, hepatitis C or human immunodeficiency virus (HIV, positive HIV 1 or 2 antibody). Active hepatitis B virus (HBV) refers to the known positive result of HBV surface antigen (HBsAg). Patients who have had HBV infection or regression in the past (referring to the presence of hepatitis B core antibody but lack of HBsAg) are eligible. Patients with positive hepatitis C virus (HCV) antibodies are only eligible if the HCV ribonucleic acid (RNA) polymerase chain reaction is negative. 7. History of allogeneic organ transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;local-regional reccurence-free survival;distant metastasis free survival;progress-free survival;safety; | — |
Countries
China
Contacts
Public ContactLu Haijun
Affiliated Hospital of Qingdao University
Outcome results
None listed